622 results match your criteria Cardiovascular Therapeutics[Journal]


Activation of AMPK alleviates cardiopulmonary bypass-induced cardiac injury via ameliorating acute cardiac glucose metabolic disorder.

Cardiovasc Ther 2018 Dec;36(6):e12482

Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

Recent years, studies have demonstrated that hyperglycemia is one of the main manifestations after cardiac surgeries, which contributes to myocardial injuries and increases the chance of subsequent complications and mortality in such patients. However, strategies targeting at glucose metabolic disorder after cardiac surgeries to attenuate myocardial injuries are inadequately studied. In this study, a rat model of cardiopulmonary bypass (CPB) was applied to investigate the role of Adenosine 5'-monophosphate-activated protein kinase (AMPK) in modulating myocardial glucose metabolic-induced cardiac injuries after cardiac surgery. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12482
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12482DOI Listing
December 2018
9 Reads

Hydromorphine postconditioning protects isolated rat heart against ischemia-reperfusion injury via activating P13K/Akt/eNOS signaling.

Cardiovasc Ther 2018 Dec;36(6):e12481

Department of Anesthesiology, Affiliated traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China.

Introduction: Myocardial ischemia/reperfusion injury (myocardial I/R injury) has a high disability rate and mortality. Novel treatments for myocardial I/R injury are necessary.

Aim: In order to explore the protective effect of hydromorphine on myocardial I/R injury, we illuminate the underlying mechanism of the protective effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12481DOI Listing
December 2018
1 Read
2.362 Impact Factor

Statins and risk of cataracts: A systematic review and meta-analysis of observational studies.

Cardiovasc Ther 2018 Dec 25;36(6):e12480. Epub 2019 Jan 25.

Laboratory of Social Pharmacy and Public Health, School of Pharmacy, University of Coimbra, Coimbra, Portugal.

Introduction: Two previous meta-analyses evaluated the risk of cataracts associated with statins, but did not include relevant studies suggesting a cataractogenic effect.

Aims: The aim of this systematic review and meta-analysis of observational studies is to evaluate such association considering the latest published evidence.

Methods: A literature search was conducted to identify observational, comparative studies evaluating the risk of developing cataracts in patients treated with statins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12480DOI Listing
December 2018
1 Read

Role of interleukin-7 in fusion of rat bone marrow mesenchymal stem cells with cardiomyocytes in vitro and improvement of cardiac function in vivo.

Cardiovasc Ther 2018 Dec 6;36(6):e12479. Epub 2018 Dec 6.

Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.

Aims: Mesenchymal stem cells (MSCs) hold significant promise as potential therapeutic candidates following cardiac injury. However, to ensure survival of transplanted cells in ischemic environment, it is beneficial to precondition them with growth factors that play important role in cell survival and proliferation. Aim of this study is to use interleukin-7 (IL-7), a cell survival growth factor, to enhance the potential of rat bone marrow MSCs in terms of cell fusion in vitro and cardiac function in vivo. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12479
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12479DOI Listing
December 2018
9 Reads

Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non-permanent atrial fibrillation.

Cardiovasc Ther 2018 Dec 28;36(6):e12478. Epub 2018 Nov 28.

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.

Aim: To investigate the upstream therapeutic effects of fluvastatin and valsartan on hypertensive patients with non-permanent atrial fibrillation (AF).

Methods: A total of 189 patients who were admitted to outpatient and inpatient department from eight medical centers in China, diagnosed as hypertension with non-permanent AF, were divided into four groups randomly: the CCBs group (group A, n = 45); CCB + fluvastatin group (group B, n = 48); valsartan group (group C, n = 46); valsartan + fluvastatin group (group D, n = 50). The four groups were followed up for 24 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12478DOI Listing
December 2018
5 Reads

Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis.

Cardiovasc Ther 2018 Dec 28;36(6):e12477. Epub 2018 Nov 28.

Department of Cardiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.

Aims: To investigate whether there exists a cardio-protective effect of Fasudil, a selective Rho kinase (ROCK) inhibitor, in an experimental murine model of acute viral myocarditis.

Methods: Male BALB/c mice were randomly assigned to three groups: control, myocarditis treated with placebo and myocarditis treated with Fasudil (n = 40 animals per group). Myocarditis was established by intraperitoneal injection with coxsackievirus B3 (CVB3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12477DOI Listing
December 2018
8 Reads

Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice.

Cardiovasc Ther 2018 Dec 29;36(6):e12476. Epub 2018 Nov 29.

Department of Pharmacy, Integrated Research Institute of Pharmaceutical Sciences, and BK21 PLUS Team for Creative Leader Program for Pharmacomics-based Future Pharmacy, College of Pharmacy, The Catholic University of Korea, Bucheon-si, Korea.

Aims: Despite the therapeutic efficacy of statins and antiplatelet agents for atherosclerosis, monotherapy with each drug alone is often insufficient to achieve the patient's therapeutic goals. We previously showed that combined statin/antiplatelet agent/anti-tumor necrosis factor (TNF) agent therapy (pravastatin/sarpogrelate/etanercept) reduces atherosclerotic lesions by inhibiting TNF, an atherogenic cytokine that contributes to the progression of arteriosclerosis. In addition, our previous study showed that combined treatment with pravastatin and cilostazol is effective for reducing TNF-driven inflammation through anti-TNF activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12476DOI Listing
December 2018
7 Reads

The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis.

Cardiovasc Ther 2018 Dec 28;36(6):e12475. Epub 2018 Nov 28.

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.

Aim: Cases of cardiotoxicity related to trastuzumab have been reported. This systematic review and meta-analysis evaluated the risk of atrial fibrillation (AF) in patients of breast cancer treated with trastuzumab.

Methods: PubMed and EMBASE were searched until September 2017 for articles that investigated AF incidence in patients receiving trastuzumab for breast cancer. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12475
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12475DOI Listing
December 2018
5 Reads

Calcium channel blockers are associated with improved survival and lower cardiovascular mortality in patients with renovascular disease.

Cardiovasc Ther 2018 Dec 4;36(6):e12474. Epub 2018 Dec 4.

Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK.

Background And Objective: Results of interventional trials in renovascular hypertension have been disappointing, and medical therapy is the current recommended gold standard. However, the comparative long-term benefits of different antihypertensive drug classes in atherosclerotic renal artery stenosis are not known. We aim to assess the effect of different antihypertensive drug classes on outcomes in renovascular hypertension DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Using Tayside Health Informatics Centre database, anonymized data over a 6-year period was analyzed. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12474
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12474DOI Listing
December 2018
19 Reads

Effects of tranexamic acid on short-term and long-term outcomes of on-pump coronary artery bypass grafting: Randomized trial and 7-year follow-up.

Cardiovasc Ther 2018 Dec 16;36(6):e12472. Epub 2018 Nov 16.

Department of Anesthesiology, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.

Aims: Safety evaluations of tranexamic acid (TXA) remain sparse, especially with respect to its impact on long-term outcomes in patients undergoing on-pump coronary artery bypass grafting (CABG). We hypothesized that the effects of TXA on perioperative bleeding and allogeneic transfusion and its impact on long-term clinical outcomes of patients receiving on-pump CABG are superior to those in the control group.

Methods: In this prospective, randomized, placebo-controlled trial, 210 patients undergoing primary and isolated on-pump CABG were randomly assigned to receive TXA or a corresponding volume of saline solution. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12472
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12472DOI Listing
December 2018
6 Reads
2.362 Impact Factor

The modifying effect of the MTHFR genotype on the association between folic acid supplementation and pulse wave velocity: Findings from the CSPPT.

Cardiovasc Ther 2018 Dec 20;36(6):e12473. Epub 2018 Nov 20.

Department of Cardiology, Chinese People's Liberation Army General Hospital, Beijing, China.

Objective: In a subgroup analysis of the China Stroke Primary Prevention Trial, we aimed to explore the impact of folic acid supplementation on arterial stiffness and assess the modifying effect of the methylenetetrahydrofolate reductase (MTHFR) gene in Chinese patients with hypertension.

Methods: This prospective study enrolled 2529 hypertensive Chinese patients. Participants were randomized to receive treatment with either a combination of enalapril and folic acid or enalapril. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12473
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12473DOI Listing
December 2018
14 Reads

Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan.

Cardiovasc Ther 2018 Dec 13;36(6):e12471. Epub 2018 Nov 13.

Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.

Elevated blood pressure (BP) is a major determinant of morbidity and mortality burden related to cardio-metabolic risk. Current guidelines indicate that controlling and lowering BP promotes cardiovascular (CV) risk reduction. Among antihypertensive agents, angiotensin receptor blockers (ARBs) are characterized by an efficacy profile equivalent to other antihypertensive agents and are provided with excellent tolerability and low discontinuation rates during chronic treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12471DOI Listing
December 2018
21 Reads

Effects of serial phlebotomy on vascular endothelial function: Results of a prospective double-blind randomized study.

Cardiovasc Ther 2018 Dec 13;36(6):e12470. Epub 2018 Nov 13.

Department of Medicine, New York University School of Medicine, New York University Langone Medical Center, New York City, New York.

Introduction: Blood donation has been proposed as a potential therapy to reduce risk of cardiovascular disease, but the effects of phlebotomy on vascular function in human subjects have not been well characterized.

Aims: We conducted a prospective randomized double-blind study to determine the effects of serial phlebotomy on vascular endothelial function in the brachial artery. Eighty-four iron-replete, non-anemic subjects were randomly assigned to one of three study treatment groups: (a) four serial phlebotomy procedures each followed by intravenous infusion of placebo normal saline; (b) four serial phlebotomy procedures each followed by intravenous infusion to replete lost iron; and (c) four serial sham phlebotomy procedures each followed by intravenous infusion of placebo normal saline. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12470
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351195PMC
December 2018
20 Reads

Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.

Cardiovasc Ther 2018 Dec 20;36(6):e12469. Epub 2018 Oct 20.

II Department of Coronary Artery Disease, Institute of Cardiology, Warsaw, Poland.

Introduction: Options for a pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with a stable coronary artery disease (CAD) are limited to amiodarone or vernakalant. Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness and, more importantly, safety in stable CAD patients, have been sparse.

Aims: To assess the effectiveness and safety of antazoline-based therapy in patients with a stable CAD undergoing pharmacological CV of short-duration AF in the emergency department (ED). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12469
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12469DOI Listing
December 2018
2 Reads

Effect of multidisciplinary cardiac rehabilitation on the response to cardiac resynchronization therapy.

Cardiovasc Ther 2018 Dec 12;36(6):e12467. Epub 2018 Oct 12.

Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.

Background: Both cardiac resynchronization therapy (CRT) and Multidisciplinary Cardiac Rehabilitation (CR) beneficially influence symptomatic status, exercise capacity, quality of life, and heart failure readmission rates. However, the interaction between both therapies remain incompletely addressed.

Methods: Consecutive CRT patients implanted in a single tertiary care center were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12467DOI Listing
December 2018
1 Read

MicroRNA-27a mediates the Wnt/β-catenin pathway to affect the myocardial fibrosis in rats with chronic heart failure.

Cardiovasc Ther 2018 Sep 20:e12468. Epub 2018 Sep 20.

Department of Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, China.

Objective: To clarify the influence of MicroRNA-27a (miR-27a)-mediated Wnt/β-catenin pathway on the myocardial fibrosis in rats with chronic heart failure (CHF).

Methods: The CHF rat models were constructed and randomly divided into four groups (Sham, Model, AntagomiR-27a, and NC antagomiR-27a groups). Echocardiography was used to test the cardiac function indexes, HE (haematoxylin-eosin) staining to observe the pathological injury of myocardium, Masson staining to analyze the collagen volume fraction (CVF), and qRT-PCR (quantitative real-time PCR) and Western blotting to detect the expressions of miR-27a and Wnt/β-catenin pathway-related proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12468DOI Listing
September 2018
4 Reads

Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats.

Cardiovasc Ther 2018 Dec 29;36(6):e12466. Epub 2018 Sep 29.

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, Tianjin, China.

Introduction: Atrial remodeling in the form of fibrosis is considered as the substrate for the development of atrial fibrillation (AF). The aim of this study was to investigate the effects of tolvaptan on chronic intermittent hypoxia (CIH) induced atrial remodeling and the mechanisms underlying such changes.

Methods: A total of 45 Sprague-Dawley rats were randomized into three groups: Control group, CIH group, CIH with tolvaptan treatment (CIH-T) group (n = 15). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12466DOI Listing
December 2018
7 Reads

Use of acetazolamide in the treatment of patients with refractory congestive heart failure.

Cardiovasc Ther 2018 Dec 29;36(6):e12465. Epub 2018 Sep 29.

CIBER in Cardiovascular Diseases (CIBERCV), Madrid, Spain.

Aims: Optimal diuretic treatment of patients with refractory congestive heart failure (CHF) remains to be elucidated. In this work, we aimed to evaluate the serial changes of functional class and surrogates of fluid overload (weight and antigen carbohydrate 125) after addition of oral acetazolamide in patients with refractory CHF. Likewise, serial changes in renal function, serum electrolytes and pH were evaluated. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12465
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12465DOI Listing
December 2018
4 Reads

Evidence-based pharmacotherapies used in the postdischarge phase are associated with improved one-year survival in senior patients hospitalized with heart failure.

Cardiovasc Ther 2018 Dec 11;36(6):e12464. Epub 2018 Sep 11.

School of Population and Global Health, The University of Western Australia, Perth, Western Australia, Australia.

Aim: Hospitalized heart failure (HF) patients have a poor prognosis postdischarge. We determined whether renin-angiotensin system inhibitors (RASI) and β-blockers dispensed to patients within 60 days post-HF hospital discharge are associated with improved 1-year survival.

Methods: A retrospective population-based study was conducted in 4897 seniors, aged 65-84 years, alive at 60 days postindex HF hospitalization in Western Australia over 2003-2008. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12464DOI Listing
December 2018
2 Reads

Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.

Cardiovasc Ther 2018 Dec 28;36(6):e12463. Epub 2018 Aug 28.

Department of Medicine, Mubarak Al-Kabeer Hospital, Ministry of Health, Kuwait City, Kuwait.

Aim: To evaluate the prevalence and impact of the prescribing of an evidence-based cardiac medication (EBM) combination on 1-month, 6-months, and 12-months all-cause mortality in patients with acute coronary syndrome (ACS).

Methods: Data were analyzed from 3681 consecutive patients diagnosed with ACS admitted to 29 hospitals in 4 Middle Eastern countries from January 2012 to January 2013. The EBM combination consisted of concurrent prescribing of an antiplatelet therapy, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), β-blocker, and a statin, at hospital discharge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12463DOI Listing
December 2018
2 Reads

TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice.

Cardiovasc Ther 2018 Oct 22;36(5):e12462. Epub 2018 Aug 22.

Section of Pediatric Critical Care, Baylor College of Medicine, Houston, Texas.

Introduction: Administration of cholic acid, or its synthetic derivative, 6-alpha-ethyl-23(S)-methylcholic acid (INT-777), activates the membrane GPCR, TGR5, influences whole body metabolism, reduces atherosclerosis, and benefits the cardiovascular physiology in mice. Direct effects of TGR5 agonists, and the role for TGR5, on myocardial cell biology and stress response are unknown.

Methods: Mice were fed chow supplemented with 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12462DOI Listing
October 2018
6 Reads

Vascular endothelial growth factor gene transfer therapy for coronary artery disease: A systematic review and meta-analysis.

Cardiovasc Ther 2018 Oct 15;36(5):e12461. Epub 2018 Aug 15.

Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Aim: It is not clear whether treatment by vascular endothelial growth factor (VEGF) gene transfer can improve myocardial ischemia through a proangiogenesis mechanism and is effective against coronary artery disease (CAD). We aimed to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) that compared VEGF gene therapy and standard treatments in CAD.

Methods: We systematically searched the PubMed, Embase, and Cochrane databases and relevant references for RCTs (published up to May 2018; no language restrictions) and performed meta-analysis using both fixed and random effects models. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12461
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12461DOI Listing
October 2018
23 Reads

Trimetazidine suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents cardiac rupture in mice with myocardial infarction.

Cardiovasc Ther 2018 Oct 12;36(5):e12460. Epub 2018 Aug 12.

Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Background/aims: Cardiac rupture (CR) is a catastrophic complication of acute myocardial infarction (MI). At present, there are no effective pharmacological strategies for preventing post-MI rupture. Here we investigated the effect of trimetazidine (TMZ) on post-MI CR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12460DOI Listing
October 2018
16 Reads

Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population.

Cardiovasc Ther 2018 Oct 14;36(5):e12459. Epub 2018 Aug 14.

Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Aim: Previous studies and national assessments indicate an undertreatment of mineralocorticoid receptor antagonists (MRA) in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate why MRA is not used to full extent.

Methods: A complete community-based heart failure population was studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175311PMC
October 2018
4 Reads

Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.

Cardiovasc Ther 2018 Oct 30;36(5):e12458. Epub 2018 Jul 30.

Department of Cardiac, Thoracic and Vascular Sciences, Cardiology Clinic, Padua University Hospital, Padua, Italy.

Background: Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH.

Purpose: Search for individual risk factors and bleeding risk scores (HAS-BLED, ATRIA and ORBIT) associated with ICHs in patients with atrial fibrillation treated with VKAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12458DOI Listing
October 2018
2 Reads

Corrigendum.

Authors:

Cardiovasc Ther 2018 08;36(4):e12443

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12443DOI Listing
August 2018
4 Reads

Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.

Cardiovasc Ther 2018 Oct 30;36(5):e12457. Epub 2018 Jul 30.

Icahn School of Medicine at Mount Sinai, Zena and Michael A. Wiener Cardiovascular Institute, New York, New York.

Aims: Catheter ablation for atrial fibrillation (AF) is associated with a transitory increase in the risk of both thromboembolic and bleeding events. Evidence on the use of nonvitamin K antagonist oral anticoagulants (NOACs) in patients undergoing AF ablation mostly comes from small observational studies, underpowered to detect differences in clinical outcomes between NOACs and vitamin K antagonists (VKAs) treated patients. This updated meta-analysis aimed to determine the safety and efficacy of periprocedural anticoagulation with NOACs compared with VKAs in AF patients undergoing catheter ablation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12457DOI Listing
October 2018
41 Reads
2.362 Impact Factor

Statins and substantially increased ALT values at baseline.

Cardiovasc Ther 2018 Oct 30;36(5):e12444. Epub 2018 Jun 30.

Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12444DOI Listing
October 2018
2 Reads

Cost-effectiveness analysis of biodegradable polymer versus durable polymer drug-eluting stents incorporating real-world evidence.

Cardiovasc Ther 2018 Oct 28;36(5):e12442. Epub 2018 Jun 28.

Department of Cardiology, National University Heart Centre, Singapore, Singapore.

Aim: Compared with second-generation durable polymer drug-eluting stents (DP-DES), the cost-effectiveness of biodegradable polymer drug-eluting stents (BP-DES) remains unclear in the real-world setting. We assessed the cost-effectiveness of BP-DES in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).

Methods: We developed a decision-analytic model to compare the cost-effectiveness of BP-DES to DP-DES over 1 year and 5 years from healthcare payer perspective. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12442
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12442DOI Listing
October 2018
9 Reads

Predicting long-term ischemic events using routine clinical parameters in patients with coronary artery disease: The OPT-CAD risk score.

Cardiovasc Ther 2018 Oct 28;36(5):e12441. Epub 2018 Jun 28.

General Hospital of Shenyang Military Region, Shenyang, China.

Background: The prognosis of patients with coronary artery disease (CAD) at hospital discharge was constantly varying, and postdischarge risk of ischemic events remain a concern. However, risk prediction tools to identify risk of ischemia for these patients has not yet been reported.

Aims: We sought to develop a scoring system for predicting long-term ischemic events in CAD patients receiving antiplatelet therapy that would be beneficial in appropriate personalized decision-making for these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12441DOI Listing
October 2018
60 Reads

Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.

Cardiovasc Ther 2018 Oct 28;36(5):e12439. Epub 2018 Jun 28.

Cardiovascular Department, Lady Davis Carmel Medical Center, Haifa, Israel.

Aim: PCSK9 inhibitors (PCSK9i) effectively lower cholesterol levels in randomized trials with reduction in cardiovascular outcomes and favorable safety profile. However, the access to PCSK9i is limited due to high cost and data regarding the use of PCSK9i in real-world practice is limited.

Methods: Data on all patients submitted for approval of PCSK9i at a regional lipid clinic, outside of clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12439DOI Listing
October 2018
4 Reads

Predictors and consequences of postdischarge gastrointestinal bleeding after percutaneous coronary intervention.

Cardiovasc Ther 2018 Oct 14;36(5):e12440. Epub 2018 Aug 14.

Department of cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Aim: To evaluate the incidence, predictors, and outcomes of postdischarge gastrointestinal bleeding (GIB) in patients underwent percutaneous coronary intervention (PCI) in a 2-year follow-up study.

Methods And Results: All consecutive patients who underwent PCI throughout 2013 were enrolled. Multivariable cox proportional hazards regression were used to identify predictors of postdischarge GIB and 2-year major adverse cardiovascular and cerebrovascular events (MACCE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12440DOI Listing
October 2018
15 Reads

Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE-/- mice.

Cardiovasc Ther 2018 Aug 28;36(4):e12438. Epub 2018 Jun 28.

ORAS Rehabilitation Hospital, Motta di Livenza, Treviso, Italy.

Introduction: Vitamin K antagonists, such as warfarin, are known to promote arterial calcification through blockade of gamma-carboxylation of Matrix-Gla-Protein. It is currently unknown whether other oral anticoagulants such as direct inhibitors of Factor Xa can have protective effects on the progression of aortic valve calcification.

Aims: To compare the effect of warfarin and rivaroxaban on the progression of aortic valve calcification in atherosclerotic mice. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12438
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12438DOI Listing
August 2018
16 Reads

Noncoding RNAs as therapeutic targets in atherosclerosis with diabetes mellitus.

Cardiovasc Ther 2018 Aug 28;36(4):e12436. Epub 2018 Jun 28.

Institute for Translational Medicine, Qingdao University, Qingdao, China.

Atherosclerosis is one of the major macrovascular complications of diabetes mellitus (DM), and it is the main cause of death from clinical observation. Among various cell types involved in this disorder, endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages play a crucial role in the occurrence and development of this disease. The regulation and stabilization of these cells are a key therapeutic strategy for DM-associated atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12436DOI Listing
August 2018
4 Reads

Chronic median nerve modulation reduces ventricular arrhythmia and improves ventricular function in a postmyocardial infarction rabbit model.

Cardiovasc Ther 2018 Aug 28;36(4):e12437. Epub 2018 Jun 28.

The Cardiac Arrhythmia Center, State Key Laboratory of Cardiovascular Disease, National Clinical Research Center of Cardiovascular Diseases, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Aim: Median nerve stimulation (MNS) is a novel neuromodulation approach for treatment of ventricular arrhythmia, but little is known about its chronic effects. The aim of this study was to investigate the effects of chronic MNS on ventricular arrhythmia and ventricular dysfunction postmyocardial infarction (MI).

Method: Two weeks after MI, 12 rabbits were randomly divided into control and MNS groups, and chronic MNS was performed in MNS group for 2 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12437DOI Listing
August 2018
4 Reads

The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.

Cardiovasc Ther 2018 Aug 7;36(4):e12435. Epub 2018 Jun 7.

Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.

Background: Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied.

Methods: We performed a single-center, prospective assessor-blinded study to determine the reverse remodeling response of sacubitril/valsartan therapy in HFrEF patients with a class I indication (New York heart Association [NYHA]-class II-IV, Left ventricular ejection fraction [LVEF] < 35%, optimal dose with Renin-Angiotensin-System-Blocker [RAS-blocker]). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12435DOI Listing
August 2018
14 Reads

β-blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats.

Cardiovasc Ther 2018 Aug 13;36(4):e12434. Epub 2018 Jun 13.

Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.

Aim: To examine the interference of β-blockers with the chemokine stromal cell-derived factor-1 (SDF-1) found in cell homing receptors, C-X-C chemokine receptor type 4 (CXCR-4) and CXCR-7, and regulatory proteins of homing pathways, we administered atenolol, carvedilol, metoprolol, and propranolol for 30 days using an orogastric tube to hypertensive rats.

Method: We collected blood samples before and after treatment and quantified the levels of SDF-1 with enzyme-linked immunosorbent assay (ELISA). On day 30 of treatment, the spontaneously hypertensive rats (SHR) were euthanized, and heart, liver, lung, and kidney tissues were biopsied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12434DOI Listing
August 2018
8 Reads

Detection of individual responses to clopidogrel: Validation of a novel, rapid analysis using thrombelastography 6s.

Cardiovasc Ther 2018 Aug 25;36(4):e12433. Epub 2018 May 25.

Coronary Research Group, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Introduction: There is potential value in testing individual response to P2Y12 inhibitors to predict ischemic and bleeding risk in patients undergoing percutaneous coronary intervention. The aims of this study were: (1) to validate the ability of a novel point of care (POC) assay, thrombelastography (TEG) 6s, to detect changes in adenosine diphosphate (ADP)-induced whole blood clotting in volunteers and patients given clopidogrel using TEG 5000 as a reference and (2) to compare a novel, rapid parameter, area under the curve at 15 minutes (AUC15), with the traditional maximum clot amplitude (MA) in TEG 6s.

Methods: A total of 25 participants were included in whom ADP-induced clotting was measured at 4 time points: (1) 12 healthy volunteers given 600 mg of clopidogrel; (2) 12 patients with ACS given 600 mg of clopidogrel; (3) 1 healthy volunteer given 600 mg of clopidogrel on 5 separate occasions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12433DOI Listing
August 2018
5 Reads

Allopurinol and endothelial function: A systematic review with meta-analysis of randomized controlled trials.

Authors:
Manal M Alem

Cardiovasc Ther 2018 Aug 24;36(4):e12432. Epub 2018 May 24.

Department of Pharmacology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Aim: Oxidative stress and endothelial dysfunction are two inter-related conditions commonly seen in patients with cardiovascular risk factors. The enzyme, xanthine oxidase, is an important contributor to these phenomena but to a variable degree in different patient populations. This meta-analysis will summarize the effect of allopurinol, an established xanthine oxidase inhibitor, on endothelial function among patients with different comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175067PMC
August 2018
4 Reads

Effects of geranylgeranylacetone upon cardiovascular diseases.

Cardiovasc Ther 2018 Aug 4;36(4):e12331. Epub 2018 May 4.

Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Heat shock proteins (HSPs) are an important family of protective proteins. They are involved actively in an array of cellular processes, including protective effects on the cardiovascular system in response to various stimuli. Increasing evidence shows that pharmacologic interventions that induce expression of HSPs may be a novel approach for the treatment of cardiovascular diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12331DOI Listing
August 2018
5 Reads

Impact of "high" implantation on functionality of self-expandable bioprosthesis during the short- and long-term outcome of patients who undergo transcatheter aortic valve implantation: Is high implantation beneficial?

Cardiovasc Ther 2018 Jun 25;36(3):e12330. Epub 2018 Apr 25.

1st Department of Cardiology, Medical School, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Aim: High position of the self-expandable bioprosthesis CoreValve/Evolut R has been proved to affect immediate hemodynamics of the valve. Whether this may have any impact on long-term procedural outcome has not been defined yet. The purpose of this study was to assess whether the final position of aortic bioprosthesis affects its long-term functionality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12330DOI Listing
June 2018
17 Reads

microRNA-181a inhibits ocular neovascularization by interfering with vascular endothelial growth factor expression.

Cardiovasc Ther 2018 Jun 24;36(3):e12329. Epub 2018 Apr 24.

Departments of Pediatrics, Physiology and Pharmacology, University of Montreal, Montreal, QC, Canada.

Aim: Excess angiogenesis or neovascularization plays a key role in the pathophysiology of several ocular diseases such as retinopathy of prematurity, diabetic retinopathy, and exudative age-related macular degeneration. microRNA-181a (miR-181a) was found highly expressed in retina and choroidal tissues. This study intends to investigate the role of miR-181a in the regulation of ocular neovascularization in different pathophysiological conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12329DOI Listing
June 2018
8 Reads

Investigating the possible mechanisms involved in adenosine preconditioning-induced cardioprotection in rats.

Cardiovasc Ther 2018 Jun 19;36(3):e12328. Epub 2018 Apr 19.

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.

Background: Adenosine is a breakdown product of adenosine triphosphate and plays an important role in pharmacological preconditioning. The cardioprotective effects of adenosine preconditioning are well established. However, the possible mechanisms need to be explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12328DOI Listing
June 2018
7 Reads

Efficacy and safety of a second-generation biodegradable polymer sirolimus-eluting stent: One-year results of the CREDIT 2 trial.

Cardiovasc Ther 2018 Jun 25;36(3):e12327. Epub 2018 Mar 25.

The 254th Hospital of PLA, Tianjin, China.

Aims: We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent.

Methods And Results: Patients (n = 419) scheduled to undergo percutaneous coronary intervention (PCI) were randomized to receive either the EXCEL 2 stent (n = 208) or the EXCEL stent (n = 211) from 15 Chinese centers. At 9 months, primary endpoint in-stent late loss (LL) difference was -0. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12327
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12327DOI Listing
June 2018
15 Reads
2.360 Impact Factor

Effects of combination of sotalol and verapamil on initiation, maintenance, and termination of ventricular fibrillation in swine hearts.

Cardiovasc Ther 2018 Jun 25;36(3):e12326. Epub 2018 Mar 25.

Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Introduction: Sotalol and verapamil alone reduce reentry incidence during ventricular fibrillation (VF). We tested whether the combination of these two drugs had a synergistic effect on initiation, maintenance, and termination of VF.

Methods: Six open-chest pigs received intravenous sotalol (1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945327PMC
June 2018
11 Reads
2.360 Impact Factor

Vascular dysfunction elicited by a cross talk between periaortic adipose tissue and the vascular wall is reversed by pioglitazone.

Cardiovasc Ther 2018 Jun 7;36(3):e12322. Epub 2018 Mar 7.

Vascular Biology Lab, Institute of Experimental Medicine and Biology of Cuyo (IMBECU) CONICET, School of Medical Sciences, National University of Cuyo, Mendoza, Argentina.

Aim: Perivascular adipose tissue (PVAT) is in intimate contact with the vessel wall and extravascular PVAT-derived inflammatory mediators may adversely influence atherosclerotic plaque formation and stability through outside-to-inside signaling. We sought to investigate the role of PVAT on the atheroma development in an experimental animal model of metabolic syndrome (MS) associated with oxidative stress and low-grade inflammatory state. We also studied the effect of pioglitazone an insulin sensitizer, on the aortic wall and its surrounding PVAT, considering a bi-directional communication between both layers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12322DOI Listing
June 2018
56 Reads

Head-to-head comparison of the heart rate variability between the bisoprolol transdermal patch and bisoprolol fumarate tablet.

Cardiovasc Ther 2018 Jun 5;36(3):e12325. Epub 2018 Mar 5.

Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Aim: The bisoprolol transdermal patch is a newly developed β-blocker designed to deliver its pharmaceutical ingredient through the skin surface. We aimed to compare the bisoprolol transdermal patch and bisoprolol fumarate tablet using the heart rate variability (HRV).

Method: Eligible hypertensive patients received a 2-week administration with a 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12325DOI Listing
June 2018
7 Reads

Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.

Cardiovasc Ther 2018 Jun 6;36(3):e12324. Epub 2018 Mar 6.

Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Aim: Prescription of statins to patients with chronic liver disease whose alanine transaminase (ALT) is over three times the upper normal limit (UNL) is not recommended. In this study, we attempted to evaluate patients with baseline ALT levels > 3 ×  UNL who were prescribed statins without ethical problems, using electronic medical records.

Methods: We enrolled subjects with ALT levels > 3 ×  UNL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12324DOI Listing
June 2018
15 Reads
2.362 Impact Factor

Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients.

Cardiovasc Ther 2018 Jun 6;36(3):e12323. Epub 2018 Mar 6.

Cardiology Unit, University and ASST Spedali Civili, Brescia, Italy.

Aim: Heart rate (HR) is an important prognostic factor in patients affected by chronic heart failure (CHF); ivabradine has been demonstrated to significantly reduce nonfatal myocardial infarction and hospitalization rate for acute heart failure and to improve left ventricular (LV) reverse remodeling, quality of life, exercise capacity, and arterial elastance (Ea) in these patients. We aimed at evaluating the short-term effects of ivabradine on ventricular-arterial coupling (VAC), aortic stiffness, and endothelial function in stable patients with CHF.

Methods: We evaluated 30 consecutive CHF patients (LVEF≤ 35%, NYHA class II) with sinus rhythm and HR ≥ 70 bpm on optimized pharmacological therapy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1755-5922.12323
Publisher Site
http://dx.doi.org/10.1111/1755-5922.12323DOI Listing
June 2018
10 Reads

Doxycycline attenuates chronic intermittent hypoxia-induced atrial fibrosis in rats.

Cardiovasc Ther 2018 Jun 2;36(3):e12321. Epub 2018 Mar 2.

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.

Introduction: Atrial structural remodeling in the form of fibrosis contributes to the arrhythmic substrate in atrial fibrillation (AF). The aim of this study was to investigate the effects of doxycycline on chronic intermittent hypoxia (CIH)-induced atrial fibrosis and the pathophysiological mechanisms underlying such changes.

Methods: A total of 30 Sprague Dawley rats were randomized into three groups: control group, CIH group, and CIH with doxycycline treatment (CIH-D) group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12321DOI Listing
June 2018
12 Reads